Radiaction Medical Ltd. Receives FDA Clearance for its Innovative Radiation Protection System and Secures $10M for US Launch and Commercialization
PR95312
TEL AVIV, Israel, April 4, 2022 /PRNewswire=KYODO JBN/ --
Radiaction Medical Ltd. [ http://www.radiactionmedical.com/ ] ("Radiaction"),
an innovative medical device company focused on radiation protection in the
interventional cardiology and electrophysiology sectors, announced FDA 510(K)
clearance for the marketing of its Shield System in the US.
In addition, the company has completed a $10 million round of financing led by
current investors, InnovaHealth Partners. Proceeds will be used to launch
Radiaction's Shield System in the US and to further commercialize in Europe.
Individuals working in catheterization laboratories ("cath labs") are exposed
to high levels of scattered radiation generated from the use of X-ray
fluoroscopy. The medical teams wear heavy lead aprons for protection, but their
heads, arms and legs are unprotected, leading to an increase in risk for brain
tumors, cognitive degradation and other radiation-related illnesses. In
addition, the heavy lead aprons can cause severe orthopedic injuries. A
significant part of the radiation is scattered throughout the cath lab by its
interaction with the patient's body and X-ray table. Mounted directly on the
C-arm, Radiaction's Shield System blocks and captures the scattered radiation
at the source. Clinical studies demonstrate that the device reduces radiation
in the entire cath lab by over 90%, with even higher reduction rates to the
head and upper body of all personnel in the room.
Jonathan Yifat, Radiaction's CEO, said, "We are very pleased with the FDA
clearance of our device and look forward to protecting the physicians and
medical personnel performing interventional procedures in the US. This
financing will drive our commercialization in the US and Europe, and allow us
to build our team and market presence. We are excited to take this next step
with our long-time partner, InnovaHealth Partners, who has tremendous
experience backing the fast commercial growth of technology companies."
About Radiaction:
Radiaction, based in Tel Aviv, Israel, has developed the Shield System to
provide a radiation-safe environment for the entire healthcare team. The
Company is revolutionizing X-ray protection by providing full-body shielding to
all medical personnel during fluoroscopy-guided procedures. Placed on the
C-arm, the Shield System encapsulates the imaging beam and blocks the scattered
radiation at its origin, creating a paradigm shift in medical staff radiation
protection. First installations will target the Interventional Cardiology and
Electrophysiology markets, where physicians experience the highest radiation
exposure.
Radiaction was founded by Amir Belson, MD and its lead investor is InnovaHealth
Partners, LP.
For more information, visit Radiaction's website at www.radiactionmedical.com
or send an email to: contact@radiactionmedical.com.
Source: Radiaction Medical Ltd.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。